Please login to the form below

Not currently logged in
Email:
Password:

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

Boehringer Ingelheim Lilly Trajenta linagliptin

European regulators have approved a new indication for Boehringer Ingelheim and Lilly's Trajenta (linagliptin) that will allow it to be used in combination with insulin to treat adults with type 2 diabetes.

The approval means Trajenta is now indicated for use in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

This brings it into line with its fellow dipeptidyl peptidase-4 (DPP-4) inhibitors AstraZeneca and BMS' Onglyza (saxagliptin) and Januvia (sitagliptin), Merck & Co's sector-leading drug.

Prof Klaus Dugi, corporate senior vice president medicine at Boehringer Ingelheim, said: “We are delighted that approval has been granted for the use of linagliptin as an add-on to insulin in adults with type 2 diabetes.

“This expanded indication shows that linagliptin is an effective treatment for patients at various stages of type 2 diabetes.”

Trajenta's latest approval was based on trials showing that after 24 weeks, adding the drug to insulin produced better glucose control than insulin alone, without an additional risk of hypoglycaemia.

Trajenta is the lead product in the diabetes alliance Boehringer and Lilly formed last year and the drug was first approved in Europe last August in combination with metformin and metformin plus sulphonylurea. It also has a licence as a monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate.

Trajenta works by increasing the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 (DPP-4).

Although not the first of the DPP-4 inhibitors to be approved, it is the first to be licensed at one dosage strength (5 mg, once daily), with no dose adjustment necessary in patients with kidney or liver impairment.

Boehringer and Lilly will be hoping to build on this advantage with their follow-up product Jentadueto, which combines Trajenta's active ingredient linagliptin with metformin and was approved in Europe over the summer.

29th October 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Waggener Edstrom

Waggener Edstrom’s global and European healthcare hub is based in London, and works with experienced teams across the globe; teams...

Latest intelligence

If you needed an organ transplant, would you have one?
Lauren Packer discusses the worsening problem in the UK with an imbalance between the number of organs needed, and the number of those being donated....
Why tugging at our heartstrings is no longer enough to make us open our purses
Charlotte Shyllon (Director and Partner) and Maren Thurow (Senior Account Executive), discuss the highly emotive Make a Child Cry campaign video from Doctors of the World (Médecins du Monde)....
quantify_messages.png
Exploring full potential of e-detailing data
Today’s high quality e-detailing data can create better quality conversations with healthcare professionals and result in improved access and relationships....

Infographics